

REMARKS

Allowed claims 13 and 63 are pending in the current application. Claims 12, 14-16, 18-35, 37, 39, 41-48, 51, 53-60 and 62 have been cancelled in this Response.

Applicants expressly reserve the right to pursue cancelled subject matter in continuing applications.

Claim Rejections under 35 USC § 112 – Scope of Enablement

Claims 12, 14-16, 18-34, 60 and 62 were rejected under 35 U.S.C. § 112, first paragraph. To expedite prosecution Claims 12, 14-16, 18-34, 60 and 62 are cancelled herein. Applicants respectfully submit that this rejection is moot and request that this rejection be withdrawn.

Claim Rejections under 35 USC § 112 – Written Description

Claims 12, 14-16, 18-34, 60 and 62 were rejected under 35 U.S.C. § 112, first paragraph. To expedite prosecution Claims 12, 14-16, 18-34, 60 and 62 are cancelled herein. Applicants respectfully submit that this rejection is moot and request that this rejection be withdrawn.

Claim Rejections under 35 USC § 112 – 2nd Paragraph

Claims 12, 14-16, 18-34, 60 and 62 were rejected under 35 U.S.C. § 112, second paragraph. To expedite prosecution Claims 12, 14-16, 18-34, 60 and 62 are cancelled herein. Applicants respectfully submit that this rejection is moot and request that this rejection be withdrawn.

CONCLUSION

Should any outstanding issues remain, the Examiner is encouraged to contact Applicants' undersigned representative.

Date: February 15, 2010
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-1891
Fax: (919) 483-7988

Respectfully submitted:



Alice P. Bradney
Attorney for Applicants
Reg. No. 51,491